{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:53:07Z","timestamp":1781693587369,"version":"3.54.5"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Reports"],"abstract":"<jats:p>Background: Pediatric influenza-like illness (ILI) represents a major global health burden. However, international treatment guidelines lack robust evidence specific to children. Umifenovir (Arbidol) is a broad-spectrum antiviral approved for pediatric use in several countries, but clinical data are fragmented and regionally limited. Methods: A comprehensive search of PubMed, Russian (RSCI, national archives, regulatory documents), and Chinese (CNKI) databases was conducted for pediatric randomized controlled trials (RCTs) and non-randomized trials comparing umifenovir to symptomatic therapy (ST) or oseltamivir. Risk of bias was assessed using the RoB 2 tool for RCTs, and ROBINS-I for non-RCTs. Outcomes included the duration of fever and other symptoms, prophylactic efficacy, and adverse events. Random-effects models were used (Hartung\u2013Knapp\u2013Sidik\u2013Jonkman approach). The review was not registered. Results: We included 16 therapeutic and eight prophylactic trials enrolling approximately 4700 and 2000 children, respectively. Compared with ST, umifenovir reduced the duration of fever (MD \u22121.41 days, 95% CI: \u22121.78 to \u22121.05), cough (\u22121.15 days, 95% CI: \u22121.50 to \u22120.79), and hospitalization. The complication risk decreased (RR 0.34, 95% CI: 0.23\u20130.51). For prophylaxis, umifenovir reduced the risk of ILI (RR 0.68, 95% CI: 0.54\u20130.87) and laboratory-confirmed influenza (RR 0.41, 95% CI: 0.29\u20130.59). Adverse events were generally mild and did not differ significantly from ST or oseltamivir (RR 0.78, 95% CI: 0.51\u20131.20). Conclusions: Umifenovir may reduce symptom duration, complications, and infection risk in pediatric ILI, with a favorable safety profile. However, the overall certainty of evidence is limited by the age of the studies, geographic restriction, and methodological quality.<\/jats:p>","DOI":"10.3390\/pediatric18030077","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T05:50:58Z","timestamp":1781157058000},"page":"77","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and Safety of Umifenovir (Arbidol) in Children with Influenza-like Illnesses: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4861-0919","authenticated-orcid":false,"given":"Vilya","family":"Bulgakova","sequence":"first","affiliation":[{"name":"Institute of Motherhood and Childhood, Pirogov Russian National Research Medical University, 117513 Moscow, Russia"},{"name":"Pediatrics and Child Health Research Institute, Petrovsky National Research Center of Surgery, 119991 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2004-3935","authenticated-orcid":false,"given":"Artem","family":"Poromov","sequence":"additional","affiliation":[{"name":"Virology Department, Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia"},{"name":"Medical Institute, Peoples\u2019 Friendship University of Russia Named After Patrice Lumumba, 117198 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Leneva","sequence":"additional","affiliation":[{"name":"Virology Department, Mechnikov Research Institute of Vaccines and Sera, 105064 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2570-711X","authenticated-orcid":false,"given":"Natalia","family":"Pshenichnaya","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Russian Medical Academy of Continuing Professional Education, Federation, 125993 Moscow, Russia"},{"name":"Central Research Institute of Epidemiology, Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), 111123 Moscow, Russia"},{"name":"Moscow Regional Clinical Researched Institute Named After M.F. Vladimirsky, 129110 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1007\/s11136-013-0606-3","article-title":"The impact of influenza-like illness in young children on their parents: A quality of life survey","volume":"23","author":"Chow","year":"2014","journal-title":"Qual. Life Res."},{"key":"ref_2","unstructured":"Ministry of Health of the Russian Federation, and Union of Pediatricians of Russia (2025, August 17). Clinical Guidelines: Acute Respiratory Viral Infection (ARVI), Available online: https:\/\/cr.minzdrav.gov.ru\/view-cr\/25_2."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s13534-024-00450-8","article-title":"AI-assisted diagnostic approach for influenza-like illness in children: Decision support system for patients and clinicians","volume":"15","author":"Lee","year":"2025","journal-title":"Biomed. Eng. Lett."},{"key":"ref_4","unstructured":"World Health Organization (2024). Clinical Practice Guidelines for Influenza, World Health Organization. Available online: https:\/\/iris.who.int\/handle\/10665\/378872."},{"key":"ref_5","unstructured":"World Health Organization (2025, August 17). Guidelines for the Clinical Management of Severe Illness from Influenza Virus Infections. Available online: https:\/\/iris.who.int\/handle\/10665\/352453."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.antiviral.2014.04.006","article-title":"Arbidol as a broad-spectrum antiviral: An update","volume":"107","author":"Blaising","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","article-title":"Arbidol: A broad-spectrum antiviral compound that blocks viral fusion","volume":"15","author":"Boriskin","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Leneva, I., Kartashova, N., Poromov, A., Gracheva, A., Korchevaya, E., Glubokova, E., Borisova, O., Shtro, A., Loginova, S., and Shchukina, V. (2021). Antiviral activity of umifenovir in vitro against a broad spectrum of coronaviruses, including the novel SARS-CoV-2 virus. Viruses, 13.","DOI":"10.3390\/v13081665"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00705-007-0974-5","article-title":"Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo","volume":"152","author":"Shi","year":"2007","journal-title":"Arch. Virol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e081165","DOI":"10.1136\/bmj-2024-081165","article-title":"Drug treatments for mild or moderate COVID-19: Systematic review and network meta-analysis","volume":"389","author":"Ibrahim","year":"2025","journal-title":"BMJ"},{"key":"ref_11","first-page":"91","article-title":"Umifenovir (Arbidol) and acute rotavirus gastroenteritis: Antiviral activity, mechanism of action, review and meta-analysis of clinical studies","volume":"14","author":"Leneva","year":"2025","journal-title":"Infect. Dis. News Opin. Train."},{"key":"ref_12","first-page":"70","article-title":"Umifenovir in China: A review of scientific and clinical data","volume":"13","author":"Leneva","year":"2024","journal-title":"Infect. Dis. News Opin. Train."},{"key":"ref_13","first-page":"844","article-title":"Comparison of the efficacy of arbidol and oseltamivir phosphate in the treatment of children with common influenza","volume":"35","author":"Liu","year":"2024","journal-title":"Mod. Diagn. Treat."},{"key":"ref_14","first-page":"317","article-title":"Effect of umifenovir hydrochloride on symptom relief and inflammatory factors in children with influenza","volume":"19","author":"Mo","year":"2025","journal-title":"China Typ. Cases Collect."},{"key":"ref_15","first-page":"56","article-title":"Clinical efficacy of umifenovir in influenza and ARVI (study ARBITR)","volume":"91","author":"Pshenichnaya","year":"2019","journal-title":"Ter. Arkh."},{"key":"ref_16","first-page":"71","article-title":"The use of domestic antiviral drugs from the standpoint of evidence-based medicine","volume":"1","author":"Petrov","year":"2011","journal-title":"Lechaschiy Vrach"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Bai, X., Xi, S., Chen, G., Fan, X., Wang, K., Li, Y., Zhao, Y., Wang, W., and Tian, Y. (2023). Multicenter, randomized controlled, open-label evaluation of the efficacy and safety of arbidol hydrochloride tablets in the treatment of influenza-like cases. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08570-9"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.jpba.2006.06.039","article-title":"Determination of arbidol in human plasma by LC\u2013ESI\u2013MS","volume":"43","author":"Liu","year":"2007","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_19","first-page":"289","article-title":"Efficacy and safety of arbidol in treatment of naturally acquired influenza","volume":"26","author":"Wang","year":"2004","journal-title":"Acta Acad. Med. Sin."},{"key":"ref_20","unstructured":"Guskova, T.A., and Glushkov, R.G. (1999). Arbidol\u2014Immunomodulator, Interferon Inducer, Antioxidant, Timotek. (In Russian)."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A revised tool for assessing risk of bias in randomized trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomized studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e64016","DOI":"10.2196\/64016","article-title":"MetaAnalysisOnline.com: Web-based tool for the rapid meta-analysis of clinical and epidemiological studies","volume":"27","author":"Fekete","year":"2025","journal-title":"J. Med. Internet Res."},{"key":"ref_24","first-page":"1150","article-title":"Experience of using arbidol in the treatment and prevention of influenza and acute respiratory viral infections in children in Ukraine","volume":"21","author":"Kramarev","year":"2003","journal-title":"Russ. Med. J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"183","DOI":"10.21518\/2079-701X-2019-2-183-187","article-title":"Antiviral therapy of ARVI in children in modern clinical practice","volume":"2","author":"Dondurey","year":"2019","journal-title":"Med. Sov."},{"key":"ref_26","first-page":"68","article-title":"Pharmacologic and epidemiologic study of influenza and ARVI in children","volume":"10","author":"Bulgakova","year":"2016","journal-title":"J. Pediatr. Infect. Dis."},{"key":"ref_27","first-page":"26","article-title":"Prevention and treatment of frequent respiratory diseases in children with weakened immune systems","volume":"11","author":"Kladova","year":"2012","journal-title":"Child. Infect."},{"key":"ref_28","first-page":"61","article-title":"Arbidol in the prevention and treatment of influenza and ARVI in children","volume":"81","author":"Uchaikin","year":"2002","journal-title":"Pediatr. n.a. G.N. Speransky"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"9371","DOI":"10.1021\/acs.jmedchem.4c03093","article-title":"Strategic design and optimization of umifenovir analogues: Balancing antiviral efficacy and hERG toxicity against SARS-CoV-2","volume":"68","author":"Hoque","year":"2025","journal-title":"J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"(2024). Rational choice of antiviral therapy for influenza and acute respiratory viral infections under the conditions of tridemic (consensus of the Expert Council). Infect. Dis. News Opin. Train., 13, 125\u2013138. (In Russian).","DOI":"10.33029\/2305-3496-2024-13-4-125-138"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Luong, Q.X.T., Hoang, P.T., Ho, P.T., Ayun, R.Q., Lee, T.K., and Lee, S. (2025). Potential broad-spectrum antiviral agents: A key arsenal against emerging respiratory RNA viruses. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26041481"},{"key":"ref_32","first-page":"29","article-title":"Chemotherapeutics for the treatment of influenza and other viral respiratory tract infections in children","volume":"43","author":"Drinevskii","year":"1998","journal-title":"Antibiot. Khimioter."},{"key":"ref_33","first-page":"34","article-title":"Evaluation of the therapeutic efficacy of arbidol in young children with acute respiratory viral infections complicated by obstructive laryngitis or obstructive bronchitis","volume":"4","author":"Cheshik","year":"2005","journal-title":"Det. Infektsii"},{"key":"ref_34","first-page":"10","article-title":"Etiotropic therapy as a means of preventing nosocomial respiratory infections in frequently ill children","volume":"2","author":"Osidak","year":"2007","journal-title":"Vopr. Prakt. Pediatr."},{"key":"ref_35","first-page":"47","article-title":"Etiological characterization and complications of acute respiratory infections in children","volume":"7","author":"Kokoreva","year":"2008","journal-title":"Curr. Pediatr."},{"key":"ref_36","first-page":"56","article-title":"Clinical and economic effectiveness of arbidol in the treatment of acute respiratory viral infections in children","volume":"24","author":"Kokoreva","year":"2013","journal-title":"Vrach"},{"key":"ref_37","first-page":"9","article-title":"Pharmacological and epidemiological study of influenza and other ARVI in the 2010\/11 season in children under 18 years","volume":"11","author":"Uchaikin","year":"2012","journal-title":"Child. Infect."},{"key":"ref_38","first-page":"46","article-title":"Comparative study of the efficacy of antiviral drugs in the complex treatment of influenza","volume":"12","author":"Baranova","year":"2014","journal-title":"Infektsionnye Bolezn."},{"key":"ref_39","first-page":"78","article-title":"Clinical efficacy assessment of antiviral medications for the management of influenza in children","volume":"93","author":"Svistunova","year":"2014","journal-title":"Pediatr. n.a. G.N. Speransky"},{"key":"ref_40","first-page":"38","article-title":"Clinical and epidemiological characteristics of acute respiratory infections in children and evaluation of antiviral therapy effectiveness","volume":"11","author":"Khmilevskaya","year":"2019","journal-title":"Zh. Infektol."},{"key":"ref_41","first-page":"24","article-title":"Estimation of epidemiological effectiveness of the pharmaceutical prevention program \u201cAntigripp\u201d in organized children\u2019s groups","volume":"11","author":"Yakovlev","year":"2012","journal-title":"Child. Infect."}],"container-title":["Pediatric Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7503\/18\/3\/77\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T10:05:44Z","timestamp":1781690744000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7503\/18\/3\/77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,9]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["pediatric18030077"],"URL":"https:\/\/doi.org\/10.3390\/pediatric18030077","relation":{},"ISSN":["2036-7503"],"issn-type":[{"value":"2036-7503","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,9]]}}}